Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do we need highly sensitive analytical techniques in phase I?

E Singlas1

  • 1Pharmacie Clinique, CHU Bicĕtre, Le Kremlin Bicêtre, France.

Fundamental & Clinical Pharmacology
|January 1, 1990
PubMed
Summary

Accurate pharmacokinetic studies are crucial for safe and effective drug development. Precise determination of drug levels and elimination rates in early trials prevents patient side-effects and speeds up clinical progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography.

Ultrasound in medicine & biology·2001
Same author

Sputum itraconazole concentrations in cystic fibrosis patients.

Antimicrobial agents and chemotherapy·2001
Same author

Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma.

Journal of chromatography. B, Biomedical sciences and applications·2000
Same author

[Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].

Pathologie-biologie·1998
Same author

Drug interactions with antiviral drugs.

Clinical pharmacokinetics·1996
Same author

Cimetidine does not alter sparfloxacin pharmacokinetics.

International journal of clinical pharmacology and therapeutics·1995

Area of Science:

  • Clinical Pharmacology
  • Drug Development
  • Pharmacokinetics

Background:

  • Pharmacokinetic (PK) studies are integral to Phase I clinical trials.
  • Drug dosage regimens in Phase II and III trials depend on PK parameters.
  • The elimination rate constant dictates dosing intervals, impacting drug efficacy and safety.

Purpose of the Study:

  • To highlight the critical role of accurate pharmacokinetic parameter determination.
  • To emphasize the consequences of inaccurate PK data in clinical drug development.
  • To underscore the importance of PK in guiding safe and efficient dosing strategies.

Main Methods:

  • Review of pharmacokinetic principles in clinical trial phases.
  • Analysis of the impact of PK parameter accuracy on drug development timelines.
  • Examination of the relationship between elimination rate and dosing interval selection.

Main Results:

  • Inaccurate determination of PK parameters can lead to unexpected drug concentrations.
  • Suboptimal dosing can result in adverse patient side effects.
  • Delays in clinical development are a consequence of unreliable PK data.

Conclusions:

  • Precise pharmacokinetic analysis is essential for successful drug development.
  • Accurate PK data ensures patient safety and optimizes therapeutic outcomes.
  • Reliable PK studies accelerate the progression of drugs through clinical trials.

Related Experiment Videos